Quick Answer
Aardvark Therapeutics, Inc. reported Cash and Equivalents of $47.05 million for fiscal year 2025.
Aardvark Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $47.05M | -23.7% |
| 2024 | $61.64M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $39.28M | — | +51.1% |
| June 30, 2025 | $26.00M | — | -1.9% |
| March 31, 2025 | $26.50M | — | -57.0% |
| December 31, 2024 | $61.64M | — | — |
- Aardvark Therapeutics, Inc. showed a decrease of -23.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Aardvark Therapeutics, Inc.’s cash and equivalents has declined by 23.7% (from $61.64 million to $47.05 million).
- The most recent figure is from Aardvark Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: